GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IGM Biosciences Inc (FRA:1K0) » Definitions » Total Receivables

IGM Biosciences (FRA:1K0) Total Receivables : €0.00 Mil (As of Dec. 2024)


View and export this data going back to 2019. Start your Free Trial

What is IGM Biosciences Total Receivables?

IGM Biosciences's Total Receivables for the quarter that ended in Dec. 2024 was €0.00 Mil.


IGM Biosciences Total Receivables Historical Data

The historical data trend for IGM Biosciences's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IGM Biosciences Total Receivables Chart

IGM Biosciences Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Receivables
Get a 7-Day Free Trial - - - - -

IGM Biosciences Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

IGM Biosciences Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables


IGM Biosciences Total Receivables Related Terms

Thank you for viewing the detailed overview of IGM Biosciences's Total Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


IGM Biosciences Business Description

Traded in Other Exchanges
Address
325 East Middlefield Road, Mountain View, CA, USA, 94043
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.

IGM Biosciences Headlines

No Headlines